viral vectors, where with a few exceptions lentivirus are used for ex vivo cell therapy and adeno-associated virus (AAV) for in vivo gene therapy, has undoubtedly benefited their rapid development and uptake for therapeutic uses. Nanoparticles, on the other hand, although generally limited to lipid or polymeric formulations, are often bespoke formulations to each laboratory. In this issue, a wide range of formulations are described including emerging technologies such as graphene nanoparticles (Vincent et al.) and exosomes (Schiffelers et al.) , as well as liposomal and polymeric formulations. Novel nanoparticles are still required for nucleic acid delivery that will be important to characterise for their chemical and biophysical properties before clinical use. This requirement for multidisciplinary approaches in addition to the efficacy of viruses may have retarded the development of nanotechnologies so far, but with the emergence of nucleic acids and therapeutic strategies that require their use, such studies acquire a new urgency.
Nanoparticles offer a wide range of applications in vivo, and may be targeted by ligands or by their innate targeting properties for organs such as the liver where nanoparticles are most advanced in their clinical development, although other targets such as inflammatory joints may be targeted systemically while the eye can be targeted by direct delivery routes (Scherman et al.) . A great deal of nanoparticle development is targeted towards cancer therapies, and an example of that is described by Jones and Merkel in this issue in developing siRNA therapies for breast cancer. A challenge here is enabling the nanoparticle to avoid the liver after systemic delivery, since many such formulations naturally accumulate in highly vascularised organs including liver, lung and spleen, reducing tumour targeting capacity.
Despite the successes with viral vectors, challenges remain including overcoming the innate and adaptive immune responses to viruses and concerns over random integration leading to insertional oncogenesis with lentiviral vectors, while arguments over links between AAV and liver cancer persist. Nanoparticles offer the opportunity to overcome such limitations, provided their efficiency levels are sufficient and moreover expand the usefulness of new nucleic acid technologies in developing therapeutics. The reviews in this issue on new nanoparticle formulations, approaches to nucleic acid delivery and therapeutic strategies are therefore a timely reminder of the potential of such systems.
